Drug Profile
Tianeptine - Servier
Alternative Names: Coaxil; Stablon; TatinolLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator French Society of Medical Research
- Developer Servier; Vela Pharmaceuticals
- Class Anxiolytics; Nootropics; Small molecules; Thiazepines; Tricyclic antidepressants
- Mechanism of Action AMPA receptor modulators; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alcoholism; Anxiety disorders; Major depressive disorder
- Discontinued Irritable bowel syndrome
Most Recent Events
- 15 Feb 2019 No development reported - Phase-III for Major depressive disorder (In the elderly) in Bulgaria, Estonia, Finland, Slovakia (PO, capsule)
- 07 Aug 2018 Launched for Major depressive disorder in China (PO)
- 01 Jan 2016 Servier completes a phase III trial in Major depressive disorder (In the elderly) in Slovakia, Finland, Estonia, Bulgaria (PO) (EudraCT2012-005612-26)